Error loading player: No playable sources found
5260
Alcohol-associated Liver Disease
Date
May 6, 2025
This product is not available for individual purchase, but it is available as part of the following products:
Don't miss the opportunity to access the latest research and discoveries in the field of digestive diseases. DDW On Demand is a valuable and convenient way to enhance your knowledge and skills in digestive disease care…
Society: AGA/AASLD
This session will delve into various aspects of managing and predicting outcomes for patients with harmful alcohol use. Attendees will learn about the association of GLP-1 agonists with liver-related outcomes, the impact of omega-5 fatty acid on cytokine profiles, and the effectiveness of oral naltrexone in promoting alcohol abstinence. Additionally, the session will cover the outcomes of patients declined for liver transplantation and the prediction of liver recompensation using the RATE score.
This session will delve into various aspects of managing and predicting outcomes for patients with harmful alcohol use. Attendees will learn about the association of GLP-1 agonists with liver-related outcomes, the impact of omega-5 fatty acid on cytokine profiles, and the effectiveness of oral naltrexone in promoting alcohol abstinence. Additionally, the session will cover the outcomes of patients declined for liver transplantation and the prediction of liver recompensation using the RATE score.
Moderators
Yale School of Medicine
Mayo Clinic Minnesota
Related Products
